Gilead Sciences Inc (GILD)vsRLX Technology Inc (RLX)
GILD
Gilead Sciences Inc
$138.26
-1.00%
HEALTHCARE · Cap: $171.45B
RLX
RLX Technology Inc
$2.21
+2.31%
CONSUMER DEFENSIVE · Cap: $2.75B
Smart Verdict
WallStSmart Research — data-driven comparison
Gilead Sciences Inc generates 714% more annual revenue ($29.44B vs $3.62B). GILD leads profitability with a 28.9% profit margin vs 25.5%. GILD trades at a lower P/E of 20.4x. GILD earns a higher WallStSmart Score of 72/100 (B).
GILD
Strong Buy72
out of 100
Grade: B
RLX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+53.9%
Fair Value
$299.95
Current Price
$138.26
$161.69 discount
Margin of Safety
+47.9%
Fair Value
$4.68
Current Price
$2.21
$2.47 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 37.4%
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Earnings expanding 23.4% YoY
Reasonable price relative to book value
Revenue surging 46.8% year-over-year
Earnings expanding 81.9% YoY
Conservative balance sheet, low leverage
Keeps 26 of every $100 in revenue as profit
Areas to Watch
4.7% revenue growth
ROE of 5.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : GILD
The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.
Bull Case : RLX
The strongest argument for RLX centers on Price/Book, Revenue Growth, EPS Growth. Profitability is solid with margins at 25.5% and operating margin at 11.0%. Revenue growth of 46.8% demonstrates continued momentum.
Bear Case : GILD
The primary concerns for GILD are Revenue Growth.
Bear Case : RLX
The primary concerns for RLX are Return on Equity.
Key Dynamics to Monitor
GILD profiles as a value stock while RLX is a growth play — different risk/reward profiles.
RLX carries more volatility with a beta of 1.23 — expect wider price swings.
RLX is growing revenue faster at 46.8% — sustainability is the question.
GILD generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
GILD scores higher overall (72/100 vs 68/100), backed by strong 28.9% margins. RLX offers better value entry with a 47.9% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gilead Sciences Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
RLX Technology Inc
CONSUMER DEFENSIVE · TOBACCO · China
RLX Technology Inc., researches, develops, manufactures, distributes and sells e-vapor products in the People's Republic of China. The company is headquartered in Beijing, China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?